- Home
- FLYX vs KZIA Comparison
FLYX vs KZIA Comparison
Compare FLYX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLYX | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | FLYX | KZIA |
|---|---|---|
| Price | $7.50 | $6.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 20.1K | ★ 250.6K |
| Earning Date | 02-22-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $362,955,000.00 | $1,199,108.00 |
| Revenue This Year | $28.47 | N/A |
| Revenue Next Year | $22.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.38 | N/A |
| 52 Week Low | $1.90 | $2.86 |
| 52 Week High | $6.90 | $17.40 |
Technical Indicators
Market Signals| Indicator | FLYX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 76.85 | 42.82 |
| Support Level | $3.08 | $5.30 |
| Resistance Level | $4.50 | $7.11 |
| Average True Range (ATR) | 0.59 | 1.22 |
| MACD | 0.21 | -0.27 |
| Stochastic Oscillator | 71.75 | 27.26 |
Price Performance
Historical ComparisonAbout FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.